Virbac S.A. stock (FR0000031577): Guidance upgrade after strong 2024 start

Virbac S.A. has raised its 2024 revenue growth and profitability guidance after a solid start to the year, putting the French animal health specialist in focus for international investors.

Virbac S.A. has tightened and raised its 2024 financial guidance after reporting solid growth in the first months of the year, sending a signal that demand for its animal health portfolio remains resilient despite macroeconomic uncertainties, according to a company trading update published in April 2024 on its investor relations site (Virbac investors as of 04/2024).

In that update, Virbac indicated that it now expects organic growth in full-year revenue toward the upper end of its prior range and a higher contribution margin, supported by strong performance in key markets and product lines, as outlined in its communication to shareholders in April 2024 (Virbac press releases as of 04/2024).

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Virbac
• Sector/industry: Animal health, veterinary pharmaceuticals
• Headquarters/country: Carros, France
• Core markets: Companion animals and livestock in Europe, North America, Latin America and Asia-Pacific
• Key revenue drivers: Prescription and preventive products for dogs, cats and food-producing animals
• Home exchange/listing venue: Euronext Paris (ticker: VIRP)
• Trading currency: EUR

Virbac S.A.: core business model

Virbac focuses exclusively on animal health, developing, manufacturing and marketing veterinary medicines, vaccines and related products for companion animals and livestock. The company positions itself as an independent specialist with a broad portfolio across parasiticides, anti-infectives, vaccines, dermatology, and nutrition, as described in its corporate profile for investors published in 2024 (Virbac about us as of 2024).

The core of the business model is to provide veterinarians with a diversified toolbox for disease prevention, treatment and health management in animals, generating recurring demand through chronic therapies, preventive care and herd health programs, according to the group’s overview for shareholders updated in 2024 (Virbac strategy as of 2024).

Virbac emphasizes research and development to differentiate its products, reporting that it allocates a mid?single?digit percentage of annual revenue to R&D activities, with a growing focus on biologicals, innovative formulations and digital tools, as noted in its full-year 2023 report published in March 2024 (Virbac annual report 2023 as of 03/2024).

The group operates a multi-local manufacturing model with production sites close to major markets, which aims to support supply reliability and regulatory compliance across regions while leveraging global scale in procurement and product development, according to its 2023 annual report released in March 2024 (Virbac annual report 2023 as of 03/2024).

Main revenue and product drivers for Virbac S.A.

Virbac reports revenue across two main animal segments: companion animals and food-producing animals, with companion animals representing the larger contributor to sales in 2023, according to the company’s annual report published in March 2024 for the 2023 financial year (Virbac annual report 2023 as of 03/2024).

Within companion animals, key product families include parasiticides for flea, tick and worm control, dermatology solutions, vaccines and specialty pharmaceuticals targeting chronic conditions in dogs and cats, as outlined in Virbac’s product portfolio overview for veterinarians updated in 2024 (Virbac products as of 2024).

On the livestock side, Virbac generates revenue from vaccines, anti-infectives and nutritional supplements for cattle, swine, poultry and other species, with a strong footprint in Latin America and Asia where animal protein production continues to expand, according to the regional breakdown included in the company’s 2023 annual report published in March 2024 (Virbac annual report 2023 as of 03/2024).

Geographically, Virbac identifies Europe, North America, Latin America and Asia-Pacific as its main regions, with the United States highlighted as a strategic market for companion animal products and vaccines, as described in its investor presentation released in 2024 (Virbac investor presentation as of 2024).

For 2023, Virbac reported consolidated revenue growth and solid profitability, citing positive contributions from price increases, mix and volume growth in several product families despite headwinds from currency and inflation, according to its full-year 2023 results announcement dated March 2024 (Virbac 2023 results as of 03/2024).

In the same announcement, the company reported that its current operating margin before depreciation of assets arising from acquisitions improved compared with the prior year, supported by operating leverage and cost discipline, although it also noted increased R&D and commercial investments to sustain long-term growth, as disclosed in March 2024 for the 2023 financial year (Virbac 2023 results as of 03/2024).

The April 2024 guidance update referenced this momentum and indicated that management expected organic revenue growth for 2024 above the initial range communicated earlier in the year, together with an improved outlook for the ratio of current operating income before amortization of assets from acquisitions to revenue, as stated in the April 2024 trading update (Virbac press releases as of 04/2024).

Conclusion

For US-focused readers, Virbac S.A. offers a pure-play view on the global animal health market through a European stock listed in Paris, with meaningful exposure to companion animals and international livestock demand. The company’s raised 2024 guidance following strong early-year trends underlines management’s confidence, but execution on its investment plans, regulatory developments and competitive dynamics in key product categories remain important variables for future performance. Currency fluctuations between the euro and the US dollar, as well as macro conditions in emerging markets where Virbac has a strong presence, also represent factors that can influence results and valuation over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.